Hafnium oxide nanoparticles as a promising emergent treatment for head and neck cancer

Multidisciplinary Head & Neck Cancers Symposium, Scottsdale, Arizona, USA · 2018, Le Tourneau C. et al.


Le Tourneau C.1, Calugaru V.1, Thariat J.O.2, Florescu C.3, Mirabel X.4, Jegoux F.5, Jouffroy T.1, Rodriguez J.1, Hoffmann C.1, Dodger B.6, Moreno Garcia V.7, Dimitriu M.8, Levy L.8, and Calvo E.6
1 – Institut Curie, Paris, France
2 – Centre Antoine-Lacassagne, Nice, France
3 – Centre Francois Baclesse, Caen, France
4 – Centre Oscar Lambret, Lille, France
5 – Centre Hospitalier Universitaire de Rennes, Rennes, FL, France
6 – START Madrid, Madrid, Spain
7 – Hospital Fundacio´n Jimenez Diaz, Madrid, Spain
8 – Nanobiotix, Paris, France


NBTXR3 administered as a single intratumoral injection and activated by radiotherapy, is currently evaluated in a phase I clinical trial for head and neck cancer [NCT01946867]. At the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale Arizona, preliminary results were presented by prof. C. Le Tourneau.

So far, patients treated in phase I showed good local and systemic tolerance to the product up to the highest dose level and received radiotherapy as planned, confirming a very good local safety profile. Regarding the patients, the durability of response so far is superior to 13 months, with some patients at 16 and 22 months follow-up without recurrence.

NBTXR3 nanoparticles constitute a rising hope for head and neck cancer patients as it could lead to a decrease in the long-term adverse effects of RT and an improvement in quality of life, associated with strong locoregional control.

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.